Jennifer K. Quint,1 Jukka Montonen,2 Daina Esposito,3 Xintong He,3 Leslie Koerner,3 Laura Wallace,4 Alberto de la Hoz,2 Marc Miravitlles5
1Population and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom; 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 3Department of Safety and Epidemiology, HealthCore, Inc, Wilmington, DE; 4Boehringer Ingelheim Corporation, Ridgefield, CT; 5Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Background
- COPD patients with high eosinophils and a history of more frequent exacerbations may benefit from treatment regimens that include ICS1
- However, maintenance treatments that include ICS are sometimes overprescribed, leading to an increased prevalence of pneumonia2,3
- Treatment with LAMA/LABA combinations, including T/O, have been shown to improve lung function versus LABA/ICS combinations2,4
- This non-interventional database study aimed to individually assess the risk of escalation to triple therapy (LAMA/LABA/ICS), exacerbation and pneumonia in COPD patients who initiated maintenance therapy with T/O versus any LABA/ICS combination
- The study also assessed the risk of an adverse outcome which was defined as any one of the events occurring (escalation to triple therapy or exacerbation or pneumonia)
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; T/O, tiotropium/olodaterol.